Last reviewed · How we verify

Factor IX (rFIXFc) — Competitive Intelligence Brief

Factor IX (rFIXFc) (Factor IX (rFIXFc)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant clotting factor (Factor IX fusion protein). Area: Hematology.

phase 3 Recombinant clotting factor (Factor IX fusion protein) Factor IX (coagulation cascade) Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Factor IX (rFIXFc) (Factor IX (rFIXFc)) — Bioverativ Therapeutics Inc.. Factor IX (rFIXFc) is a recombinant clotting factor IX fused to the Fc domain of human immunoglobulin G, which replaces deficient Factor IX to restore blood coagulation in hemophilia B patients.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Factor IX (rFIXFc) TARGET Factor IX (rFIXFc) Bioverativ Therapeutics Inc. phase 3 Recombinant clotting factor (Factor IX fusion protein) Factor IX (coagulation cascade)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant clotting factor (Factor IX fusion protein) class)

  1. Bioverativ Therapeutics Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Factor IX (rFIXFc) — Competitive Intelligence Brief. https://druglandscape.com/ci/factor-ix-rfixfc. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: